Krystal Biotech (KRYS) said Wednesday that preliminary results from its Kyanite-1 clinical trial showed "early evidence" of monotherapy activity that was mostly seen in participants with advanced non-small cell lung cancer.
The company is evaluating inhaled KB707, a modified HSV-1 vector, to treat solid tumors in the lung, it added.
The objective response rate in the trial was 27%, while the disease control rate was 73% as of Dec. 6, the company said.
Krystal Biotech said the first participant in the trial was dosed on April 17, while a total of 37 patients were enrolled who received at least one dosage of inhaled KB707, which has been "safe and generally well tolerated" to date.
Based on the initial results, Krystal Biotech said it has amended the Kyanite-1 protocol to include two groups evaluating inhaled KB707 in combination with either anti-programmed cell death protein 1 therapy or anti-PD-1 therapy and chemotherapy.
Shares of the company rose 4.4% in recent Wednesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。